Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 11

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 11
---
 this prospectus and the documents that we reference in this prospectus
and have filed with the SEC as exhibits to the registration statement, of which this prospectus is a part, completely and with the understanding
that our actual future results may be materially different from any future results expressed or implied by these forward-looking statements.

The forward-looking statements
in this prospectus represent our views as of the date of this prospectus. We anticipate that subsequent events and developments will cause
our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current
intention of doing so except to the extent required by applicable law. You should therefore not rely on these forward-looking statements
as representing our views as of any date subsequent to the date of this prospectus.

This prospectus contains market
data and industry forecasts that were obtained from industry publications. These data involve a number of assumptions and limitations,
and you are cautioned not to give undue weight to such estimates. While we believe the market position, market opportunity and market
size information included in this prospectus is generally reliable, such information is inherently imprecise.

<div align='center'>COMMONLY USED DEFINED TERMS</div>

Unless the context otherwise
requires, in this registration statement references to:

| ● | “505(b)(2) Application” refers to an application for which one or more of the investigations relied upon by the applicant for approval “were not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use from the person by or for whom the investigations were conducted” (21 U.S.C. 355(b)(2)). |
| ● | “A*STAR” refers to Agency for Science, Technology and Research.                                                                                                                                                                                                                                                                                      |
| ● | “Acticule” refers to Acticule Life Sciences Limited, an 80% owned subsidiary of Aptorum Group.                                                                                                                                                                                                                                                       |
| ● | “AD” refers to Alzheimer’s disease.                                                                                                                                                                                                                                                                                                                  |

<div align='center'>iii</div>

| ● | “Aeneas Group” refers to Aeneas Limited and its subsidiaries. Aeneas Limited is 76.8% owned by Jurchen Investment Corporation. Because Mr. Huen, a director, holds 100% equity interest in Jurchen Investment Corporation, we refer Aeneas Group as a subsidiary of Aptorum Group. |
| ● | “AML” refers to Aptorum Medical Limited, a 90